Salmonella [serotypes typhimurium, enteritidis, typhi] vaccine is under clinical development by Bharat Biotech and currently in Phase I for Salmonella typhi Infections. According to GlobalData, Phase I drugs for Salmonella typhi Infections have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Salmonella [serotypes typhimurium, enteritidis, typhi] vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Salmonella [serotypes typhimurium, enteritidis, typhi] vaccine overview
Vaccine candidate is under development for the prevention of invasive salmonella infections including serotypes S. typhimurium, S. typhi and S. enteritidis. It is a trivalent Salmonella (S. Enteritidis/S. Typhimurium/S. Typhi Vi) conjugate vaccine (TSCV), a Half-Strength Formulation of TSCV, and a Dilutional Half-Strength Dose of TSCV. It is administered through intramuscular route.
Bharat Biotech overview
Bharat Biotech discovers, develops and manufactures vaccines and bio-therapeutics. Its offers vaccines for haemophiles influenza type B (Hib), poliomyelitis, hepatitis B, Japanese encephalitis, diphtheria, tetanus, whooping cough, typhoid, swine flu (H1N1) and rabies. The company also provides probiotic yeast, Zinc with oral rehydration salts for acute diarrhea; and bio-therapeutics with recombinant epidermal growth factor (EGF) for burns, bed sores, skin grafts and diabetic foot ulcers. It is investigating bio-antibiotics, lysostaphin, recombinant staphylokinase injection, and combination probiotics and vaccine candidates for zika, chikungunya, typhoid, sabin, acellular pertussis, and human papillomavirus and malaria. Bharat Biotech is headquartered in Hyderabad, Telangana, India.
For a complete picture of Salmonella [serotypes typhimurium, enteritidis, typhi] vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
